Literature DB >> 14617785

Replication and episomal maintenance of Epstein-Barr virus-based vectors in mouse embryonal fibroblasts enable synthetic lethality screens.

Yulia Einav1, Elena Shistik, Michal Shenfeld, Arnold H Simons, David W Melton, Dan Canaani.   

Abstract

Recently, we demonstrated the establishment of chemical and genetic synthetic lethality screens in cultured human cells. Here, we report the establishment of this method in mouse embryonal fibroblasts (MEF). The method employs an immortalized mammalian cell line, deficient in a gene of interest, which is complemented by an episomal survival plasmid expressing the wild-type cDNA for the gene of interest and the use of a novel green fluorescent protein (GFP)-based double-label fluorescence system. The crucial part in this endeavor has been the identification of a DNA replicon that could stably replicate in MEFs while under selection for survival and gets spontaneously lost relatively fast in the absence of such a pressure. Here, we show for the first time that EBV-based replicons but not polyoma virus-based ones can replicate and be stably maintained in MEFs. In the chemical screen, selective pressure imposed by synthetic lethal drugs prevented the spontaneous loss of the GFP-marked episome, enabling drug identification. Retention or spontaneous loss over time of the episomal survival plasmid could be sensitively detected in a large-scale blind test in the presence or absence of synthetic lethal chemicals, respectively. Establishing the synthetic lethality screen should thus permit high throughput screening for chemicals, which are synthetically lethal with any mouse mutant/knockout gene of interest. Moreover, it forms the basis for a genetic synthetic lethality screen in MEFs, an important new tool for mouse functional genomics.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14617785

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  6 in total

1.  Lsh is involved in de novo methylation of DNA.

Authors:  Heming Zhu; Theresa M Geiman; Sichuan Xi; Qiong Jiang; Anja Schmidtmann; Taiping Chen; En Li; Kathrin Muegge
Journal:  EMBO J       Date:  2006-01-05       Impact factor: 11.598

Review 2.  Harnessing synthetic lethal interactions in anticancer drug discovery.

Authors:  Denise A Chan; Amato J Giaccia
Journal:  Nat Rev Drug Discov       Date:  2011-05       Impact factor: 84.694

3.  Back to the future: mechanism-based, mutation-specific combination chemoprevention with a synthetic lethality approach.

Authors:  Frank L Meyskens; Eugene W Gerner
Journal:  Cancer Prev Res (Phila)       Date:  2011-05

4.  A novel multiplex cell viability assay for high-throughput RNAi screening.

Authors:  Daniel F Gilbert; Gerrit Erdmann; Xian Zhang; Anja Fritzsche; Kubilay Demir; Andreas Jaedicke; Katja Muehlenberg; Erich E Wanker; Michael Boutros
Journal:  PLoS One       Date:  2011-12-05       Impact factor: 3.240

5.  Ex vivo response to histone deacetylase (HDAC) inhibitors of the HIV long terminal repeat (LTR) derived from HIV-infected patients on antiretroviral therapy.

Authors:  Hao K Lu; Lachlan R Gray; Fiona Wightman; Paula Ellenberg; Gabriela Khoury; Wan-Jung Cheng; Talia M Mota; Steve Wesselingh; Paul R Gorry; Paul U Cameron; Melissa J Churchill; Sharon R Lewin
Journal:  PLoS One       Date:  2014-11-19       Impact factor: 3.240

Review 6.  Methodological approaches in application of synthetic lethality screening towards anticancer therapy.

Authors:  D Canaani
Journal:  Br J Cancer       Date:  2009-03-24       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.